SCHEMBL1047283

SCHEMBL1047283

Cc1ccc(-c2c(Cl)cccc2Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.42
HPGD P15428 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GRIA1 P42261 2/20 0.41
CACNG8 Q8WXS5 2/20 0.41
PTGS2 P35354 1/20 0.41
SRC P12931 1/20 0.41
FABP3 P05413 2/20 0.41
FABP4 P15090 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
ACHE P22303 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29116274 0.82 CA2 (0.39) PBRM1HPGDCYP2D6CYP2C9ALOX15
SCHEMBL14887253 0.81 ALDH1A1 (0.42) PBRM1HPGDCYP2D6CYP2C9ALOX15
SCHEMBL7636229 0.80 GRIA1 (0.52) HPGDGRIA1CACNG8ALDH1A1KDM4E
SCHEMBL1046307 0.80 AHR (0.54) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL20904470 0.80 AHR (0.42) HPGDCYP2D6CYP2C9ALOX15CYP2C19
SCHEMBL1047922 0.79 CNR2 (0.50) CYP2A6
SCHEMBL1044029 0.79 ACHE (0.44) GRIA1CACNG8SRCTDP1ACHE
SCHEMBL4456487 0.79 CYP1A2 (0.50) HSD17B10GRIA1CACNG8FABP3FABP4
SCHEMBL20072696 0.78 GRIA1 (0.47) GRIA1CACNG8SRCTDP1ALDH1A1
SCHEMBL14670464 0.76 GRIA1 (0.39) HPGDCYP2D6GRIA1CACNG8L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2015-08-13 US disclosed
US-8987304-B2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
EP-2326618-B1 GLUCAGON ANTAGONISTS METABASIS THERAPEUTICS INC (US) 2014-10-15 EP disclosed
EP-2269694-A2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-01-05 EP disclosed
WO-2010019830-A1 GLUCAGON ANTAGONISTS METABASIS THERAPEUTICS, INC. (US) 2010-02-18 WO disclosed
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-11-05 US disclosed
WO-2008012413-A2 PYRIMIDINONE DERIVATIVES AND THEIR USE AS A DRUG SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PBRM1 539/4885HPGD 1700/4885CYP2D6 5/4885
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PBRM1 539/4885HPGD 1700/4885CYP2D6 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.